However, confounding issues such as the use of different methodologies and limited demographic and clinical history for each individual reduce the usefulness of this dataset.In summary, 21.5% of individuals with HCV genotype 1a have a variation at one or more drug resistance sites, 44.4% for 1b and 41.8% for 3a.